|本期目录/Table of Contents|

[1]王晓萍,丰俊东.放射治疗与分子靶向药物在肿瘤治疗中的联合应用[J].医学研究与战创伤救治(原医学研究生学报),2008,10(04):277.
点击复制

放射治疗与分子靶向药物在肿瘤治疗中的联合应用()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第10卷
期数:
2008年04期
页码:
277
栏目:
综述
出版日期:
2008-07-20

文章信息/Info

Title:
-
文章编号:
1672-271X(2008)04-0277-04
作者:
王晓萍; 丰俊东
解放军第81医院全军肿瘤中心，江苏南京210002
Author(s):
-
关键词:
放射治疗; 肿瘤分子靶向治疗; 分子靶向药物
Keywords:
-
分类号:
R730.5
DOI:
-
文献标志码:
A
摘要:
-
Abstract:
-

参考文献/References:

[1]N Ygren P,Sorbye H,Osterlund P,et al.Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab : an acta oncological expert report ［J］.Acta Oncol,2005，44 (3) : 2032-2037.
[2］Dong WK,Jessica H,Allie F,et al.Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy［J］.Int J Radiat Oncol Biology Phys,2006 ,64:38-46.
[3］Huang SM, Harari PM.Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair cell cycle kinetics, and tumor angiogenesis［J］.Clin Cancer Res, 2000, 6:2166-2174.
[4］Akimoto T,Hunte NR,Buchmiller L,et al.Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas ［J］.Clin Cancer Res,1999,5:2884-2890.
[5］Barker FG,Simmons ML,Chang SM,et al.EGFR overexpression and radiation response in glioblastoma multiforme［J］.Int J Radiat Oncol Biol Phys,2001,51:410-418.
[6］Chu E.Cetuximab targeted therapy:a new treatment paradigm for advanced colorectal cancer［J］.Clin Colorectal Cancer, 2004, 3(4) :205-210.
[7］Robert F,Ezekiel MP,Spencer SA,et al.Phase Ⅰstudy of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer［J］.J Clin Oncol, 2001, 19:3234-3243.
[8］ Bonner JA, Harari PM,Giralt JL.Cetuximab (Erbitux TM) prolongs survival in patients with locally advanced squamous cell carcinoma of the head and neck:a phase Ⅲ study of high dose radiation therapy with and without cetuximab［J］.Pro Am Soc Clin Oncol,2004,23:5507.
[9］Shintani S,Li C,Mihara M,et al.Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa,ZD1839), an epidermal growth factor recptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer［J］.Int J Cancer, 2003,107:1030-1037.
[10］Solomon BM,Hagekyriakou J,Trivett MK,et al.EGFR bloc- kade with ZD1839 (Iressa) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma［J］.Int J Radiat Oncol Biol Phys,2003,55:713-723.
[11］Huang SM,Li J,Armstront EA,et al.Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa)［J］.Cancer Res,2002,62:4300-4306.
[12］Chinnaiyan P,Huang S,Vallabhaneni G,et al.Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)［J］.Cancer Res,2005,65(8):3328-3335.
[13］Huber PE,Bischof M,Jenne J,et al.Trimodal cancer eatment:beneficial effects of combined antiangiogenesis,radiation,and chemotherapy［J］.Cancer Res,2005,65(9):3643-3655.
[14］Geng L,Donnelly E,McMahon G,et al.Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy［J］.Cancer Res,2001,61(6):2413-2419.
[15］Wachsberger P,Burd R,Dicker AP.Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents:exploring mechanisms of interaction［J］.Clin Cancer Res,2003,9(6):1957-1971.
[16］Barbara F,Dan G,Cataldo B,et al.ZD6474,an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy［J］.Int J Radiat Oncol Biology Phys,2006,64:33-37.
[17］Gustafson DL,Merz AL，Zirrolli JA，et al.Impact of scheduling on combined ZD6474 and radiotherapy in head and neck tumor xenografts［J］.Eur J Cancer，2004，Suppl 2:45-46.
[18］Shibuya K,Komaki R，Wu W，et al.Targeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small-cell lung cancer［J］.Int J Radiat Oncol Biol Phys，2004，60:S145-S146.
[19］Siemann D，Shi W.The VEGFR2 tyrosine kinase inhibitor,ZD6474,enhances the antitumor effect of radiation［J］. Eur J Cancer，2004,Suppl 2:49.
[20］Yokoyama Y,Ramakrishnan S.Improved biological activity of amutant endostatin containing a single amino-acid substitution ［J］.Br J Cancer,2004,90 (8) : 1627-1635.
[21］Shia WY,Teschendorf C,Muzyczka N,et al.Gene therapy delivery of endostatin enhances the treatment efficacy of radiation［J］.Radiother Oncol,2003,66:1-9.
[22］Kami K,Doi R,KoizumiM,et al.Survivin expression is a prognostic marker in pancreatic cancer patients ［J］.Surgery,2004,136 (2) : 443-448.
[23］Lu B,Mu Y,Cao C,et al.Survivin as a therapeutic target for radiation sensitization in lung cancer ［J］.Cancer Res,2004,64(8) : 2840-2845.
[24］R ¨O del F,Hoffmann J,Distel L,et al.Survivin as a radioresistance factor,and prognostic and therapeutic target for radiotherapy in rectal cancer［J］.Cancer Res,2005,65 (11):4881-4887.
[25］Milas L.Cyclooxygenase-2(Cox-2) enzyme inhibitors as potential enhancers of tumour radioresponse［J］.Semin Radiat Oncol,2001,11:290-299.
[26］Raju U,Nakata E,Yang P,et al.In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: Mechanistic considerations［J］.Int J Radiat Oncol Biol Phys,2002,54:886-894.
[27］Pyo H,Choy H,Amorino GP,et al.A selective cyclooxygenase-2 inhibitor,SN-398,enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2［J］.Clin Cancer Res,2001,7:2998-3005.
[28］Kishi K,Petersen S,Petersen C,et al.Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor［J］.Cancer Res, 2000,60:1326-1331.
[29］Nakata E,Mason KA,Hunter N,et al.Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors［J］.Int J Radiat Oncol Biol Phys,2004,58(2):369-375.
[30］Lordick F,Von Schilling C,Bemhard H,et al.Phase Ⅱ trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer ［J］.Br J Cancer,2003,89(4):630-633.

相似文献/References:

[1]邓 兰,马春曦,彭国林,等.食管癌放射治疗CT模拟定位[J].医学研究与战创伤救治(原医学研究生学报),2013,15(03):244.[doi:10.3969/j.issn.1672-271X.2013.03.012]
　DENG Lan,MA Chun-xi,PENG Guo-lin,et al.CT simulation in radiotherapy for esophageal carcinoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(04):244.[doi:10.3969/j.issn.1672-271X.2013.03.012]
[2]徐志明,阎利,潘晓东.放疗项目辐射防护管理的探讨——以射波刀防护为例[J].医学研究与战创伤救治(原医学研究生学报),2017,19(01):106.[doi:10.3969/j.issn.1672-271X.2017.01.030]
[3]王茂鑫,陈贤明,张贤,等.环指蛋白8在鼻咽癌组织中的表达及其与预后的关系[J].医学研究与战创伤救治(原医学研究生学报),2019,21(02):147.[doi:10.3969/j.issn.1672-271X.2019.02.007]
　WANGMao-xin,CHENXian-ming,ZHANGXian,et al.Expression of RNF8 in nasopharyngeal carcinoma and its relationship with prognosis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(04):147.[doi:10.3969/j.issn.1672-271X.2019.02.007]
[4]蒋康,陆恒,廖婉玉,等.内镜下支架置入治疗食管癌放疗后食管狭窄的疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2020,22(2):200.[doi:10.3969/j.issn.1672-271X.2020.02.019]
[5]王茂鑫,陈贤明,龚宏勋,等.siRNA沉默环指蛋白8基因对裸鼠人鼻咽癌移植瘤放疗增敏作用的实验研究[J].医学研究与战创伤救治(原医学研究生学报),2021,23(03):244.[doi:10.3969/j.issn.1672-271X.2021.03.005]
　WANG Mao-xin,CHEN Xian-ming,GONG Hong-xun,et al.Silencing RNF8 by siRNA enhances the radiation sensitivity of NPC transplantation tumor in nude mice[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(04):244.[doi:10.3969/j.issn.1672-271X.2021.03.005]
[6]杨文翠,秦士钊,陆军.乳腺托架联合真空垫在乳腺癌术后放射治疗中的应用分析[J].医学研究与战创伤救治(原医学研究生学报),2023,25(3):251.[doi:10.3969/j.issn.1672-271X.2023.03.006]
　YANG Wencui,QIN Shizhao,LU Jun.Analysis and applications of breast bracket combined with vacuum pad in postoperative radiation therapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(04):251.[doi:10.3969/j.issn.1672-271X.2023.03.006]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2013-11-22